Travaux scientifiques

Uzm. Dr. Gündüzalp Buğrahan Babacan

21 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Prognostic value of PSMA PET–derived tumor volume in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

    Cancer Imaging, 2026

    DOI 10.1186/s40644-026-01036-6 PMID 42063136 Texte intégral en libre accèsSource : OpenAlex

  2. Diffuse Gastric Uptake and Metabolic Superscan in the Patient with Multiple Myeloma

    Molecular imaging and radionuclide therapy, 2026

    DOI 10.4274/mirt.galenos.2026.43765 PMID 42334005 Texte intégral en libre accèsSource : Europe PMC

  3. Is Eligibility Enough? Pretreatment Prediction of Failure to Reach a Second Cycle of [177Lu]Lu-PSMA Radioligand Therapy

    Diagnostics, 2026

    DOI 10.3390/diagnostics16203359 PMID 42938199 Texte intégral en libre accèsSource : ORCID

  4. Novel heterogeneity method for predicting survival in non-metastatic triple-negative breast cancer

    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), 2025

    DOI 10.1016/j.remnie.2025.500112 PMID 39921170 Source : ORCID

  5. Nuevo método de heterogeneidad para predecir la supervivencia en el cáncer de mama triple negativo no metastásico

    Revista Española de Medicina Nuclear e Imagen Molecular, 2025

    DOI 10.1016/j.remn.2025.500112 Source : ORCID

  6. The effect of digital PET/CT and reconstruction algorithms on semi-quantitative values and Deauville scoring in patients with lymphoma.

    PubMed, 2025

    DOI 10.1967/s002449912904 PMID 41389257 Source : OpenAlex

  7. Comparison of different response evaluation criteria in interim PET/CT for diffuse large B-cell lymphoma: is Δtotal metabolic tumor volume a worthwhile measure?

    Nuclear Medicine Communications, 2025

    DOI 10.1097/mnm.0000000000002047 PMID 40910350 Source : ORCID

  8. Relación entre el estado de HER2 adquirido a partir de los datos patológicos y los parámetros metabólicos obtenidos mediante [18F]FDG PET/TC pretratamiento en adenocarcinomas gástricos

    Revista Española de Medicina Nuclear e Imagen Molecular, 2025

    DOI 10.1016/j.remn.2024.500080 Source : ORCID

  9. Utilidad de la PET/TC con [18F]FDG más allá de la estadificación: importancia pronóstica de la sarcopenia y del metabolismo del tejido adiposo en el carcinoma esofágico

    Revista Española de Medicina Nuclear e Imagen Molecular, 2025

    DOI 10.1016/j.remn.2024.500090 Source : ORCID

  10. [18F]FDG PET/CT beyond staging: Prognostic significance of sarcopenia and adipose tissue metabolism in esophageal carcinomas

    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), 2025

    DOI 10.1016/j.remnie.2024.500090 PMID 39732336 Source : ORCID

  11. Is There Novel 18F-FDG Biodistribution in the Digital PET/CT Era? A Real-World Data Analysis

    Cancer Biotherapy and Radiopharmaceuticals, 2025

    DOI 10.1089/cbr.2024.0226 PMID 39866138 Source : ORCID

  12. Genetic mutations and prognostic indicators in differentiated thyroid cancer: a molecular perspective

    Turkish journal of medical sciences, 2025

    DOI 10.55730/1300-0144.5944 PMID 40104288 2 citations (Europe PMC) Texte intégral en libre accèsSource : Europe PMC

  13. Evaluating the correlation between pretreatment 18F-FDG PET/CT metabolic parameters and tumor-infiltrating lymphocyte levels in nonluminal breast cancer and impact on survival

    Pathology & Oncology Research, 2025

    DOI 10.3389/pore.2024.1612014 PMID 39839836 5 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  14. Unusual Presence of Synchronous Primary Ovarian and Thyroid Extranodal Non-Hodgkin Lymphoma Without Lymph Node Involvement

    Clinical Nuclear Medicine, 2024

    DOI 10.1097/rlu.0000000000005108 PMID 38350088 2 citations (OpenAlex) Source : OpenAlex

  15. The effect of reconstruction algorithms on semi-quantitative measurements in 18F-FDG PET/CT imaging.

    PubMed, 2024

    DOI 10.1967/s002449912721 PMID 39097805 2 citations (OpenAlex) Source : OpenAlex

  16. The relationship between HER2 status acquired from pathological data and metabolic parameters from pre-treatment [18F]FDG PET/CT in gastric adenocarcinomas

    Revista Española de Medicina Nuclear e Imagen Molecular (English Edition), 2024

    DOI 10.1016/j.remnie.2024.500080 PMID 39710040 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  17. Follicular Thyroid Carcinoma with Unusual Mandible Metastasis

    Indian Journal of Nuclear Medicine, 2024

    DOI 10.4103/ijnm.ijnm_6_24 PMID 38989304 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  18. Comparison of the 68Ga-FAPI Versus 18F-FDG in Gastric Adenocarcinoma and Anthracosis-Associated Lymph Nodes: FAPI Unmasking False-Negatives and False-Positives

    Clinical Nuclear Medicine, 2024

    DOI 10.1097/rlu.0000000000005026 PMID 38271247 2 citations (OpenAlex) Source : OpenAlex

  19. Comparison of Radioactive Iodine Activities in Terms of Short- and Long-term Results in Ablation Therapy in Patients with Low-risk Differentiated Thyroid Cancer

    Molecular imaging and radionuclide therapy, 2023

    DOI 10.4274/mirt.galenos.2022.05826 PMID 37337764 4 citations (Europe PMC) Texte intégral en libre accèsSource : Europe PMC

  20. Unusual spread of the follicular thyroid carcinoma, metastases to liver and pancreas

    Médecine Nucléaire, 2023

    DOI 10.1016/j.mednuc.2023.03.010 Source : ORCID

  21. Meningioma Mimicking Bone Metastasis in Breast Cancer

    Molecular Imaging and Radionuclide Therapy, 2023

    DOI 10.4274/mirt.galenos.2022.31032 PMID 37337873 Texte intégral en libre accèsSource : ORCID